InStride Health Raises $30M in Series B Funding

InStride Health

InStride Health, a Boston, MA-based provider of specialty pediatric anxiety and OCD treatment, raised $30M in Series B funding.

The round was led by General Catalyst with participation from previous investors .406 Ventures, Valtruis, Mass General Brigham Ventures, and Hopelab Foundation. 

The company intends to use the funds to continue investing in clinical quality and expand to new markets.

Led by CEO John Voith, InStride Health provides specialty outpatient care for pediatric Anxiety and Obsessive Compulsive Disorder (OCD) and related presentations. Its care model is grounded in evidence-based treatments: Cognitive Behavioral Therapy (CBT) and Acceptance and Commitment Therapy (ACT) with a focus on Exposure and Response Prevention (ERP). A dedicated team of a psychiatrist, therapist, and an exposure coach are paired with each child to provide real-time support using everyday tools like text and a video- and chat-enabled mobile application.

InStride Health accepts most major insurance plans in the states it serves, and treatment typically begins within 1 to 4 weeks of application approval–making care affordable and accessible to more young people in need.

Commenting on the news, John Voith said: “We’re on a mission to help kids, teens, and young adults with anxiety and OCD. We aim to expand our specialty clinical services to provide the same care and accessibility we’d want for our loved ones. Thanks to the dedication of our amazing team, partners, and investors, we are thrilled to continue to expand our supportive ecosystem for the kids and families we serve.